Spark Therapeutics Inc. (ONCE) CEO Sells $626,800.00 in Stock
Spark Therapeutics Inc. (NASDAQ:ONCE) CEO Jeffrey D. Marrazzo sold 10,000 shares of the stock in a transaction on Friday, September 16th. The stock was sold at an average price of $62.68, for a total transaction of $626,800.00. Following the transaction, the chief executive officer now directly owns 240,000 shares in the company, valued at $15,043,200. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of Spark Therapeutics Inc. (NASDAQ:ONCE) opened at 62.21 on Friday. The stock’s market cap is $1.90 billion. The company’s 50-day moving average is $59.11 and its 200-day moving average is $47.56. Spark Therapeutics Inc. has a 12-month low of $21.20 and a 12-month high of $66.00.
Spark Therapeutics (NASDAQ:ONCE) last announced its earnings results on Wednesday, August 10th. The company reported ($1.04) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.97) by $0.07. Spark Therapeutics had a negative net margin of 366.76% and a negative return on equity of 26.96%. The business had revenue of $1.29 million for the quarter, compared to the consensus estimate of $1.17 million. During the same quarter last year, the firm posted ($0.60) EPS. The business’s quarterly revenue was up .0% on a year-over-year basis. On average, equities research analysts anticipate that Spark Therapeutics Inc. will post ($3.96) earnings per share for the current year.
Several hedge funds have recently made changes to their positions in the stock. Capital Fund Management S.A. acquired a new stake in shares of Spark Therapeutics during the second quarter worth approximately $348,000. Alps Advisors Inc. boosted its stake in shares of Spark Therapeutics by 26.4% in the second quarter. Alps Advisors Inc. now owns 38,489 shares of the company’s stock worth $1,968,000 after buying an additional 8,041 shares during the period. American Century Companies Inc. boosted its stake in shares of Spark Therapeutics by 5.6% in the second quarter. American Century Companies Inc. now owns 394,995 shares of the company’s stock worth $20,196,000 after buying an additional 20,995 shares during the period. Candriam Luxembourg S.C.A. boosted its stake in shares of Spark Therapeutics by 80.0% in the second quarter. Candriam Luxembourg S.C.A. now owns 54,000 shares of the company’s stock worth $2,761,000 after buying an additional 24,000 shares during the period. Finally, Amici Capital LLC acquired a new stake in shares of Spark Therapeutics during the first quarter worth approximately $443,000. Hedge funds and other institutional investors own 78.79% of the company’s stock.
Several research analysts recently issued reports on ONCE shares. Cantor Fitzgerald reissued a “buy” rating on shares of Spark Therapeutics in a research note on Thursday, July 14th. SunTrust Banks Inc. upped their price objective on shares of Spark Therapeutics from $64.00 to $72.00 and gave the stock a “buy” rating in a report on Tuesday, June 21st. Zacks Investment Research upgraded shares of Spark Therapeutics from a “hold” rating to a “buy” rating and set a $66.00 price objective on the stock in a report on Thursday, August 11th. Stifel Nicolaus started coverage on shares of Spark Therapeutics in a report on Friday, September 2nd. They set a “buy” rating and a $73.00 price objective on the stock. Finally, Jefferies Group restated a “hold” rating on shares of Spark Therapeutics in a report on Friday, August 5th. Two analysts have rated the stock with a sell rating, five have issued a hold rating and eight have assigned a buy rating to the company’s stock. Spark Therapeutics has a consensus rating of “Hold” and a consensus price target of $62.27.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc (Spark) is engaged in developing products in the field of gene therapy. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its SPK-RPE65 (voretigene neparvovec) targets genetic blinding conditions known as inherited retinal dystrophies (IRDs).
Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.